Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ECE1 | P42892 | 6/20 | 0.64 |
| ▸ | MMP2 | P08253 | 7/20 | 0.63 |
| ▸ | MMP9 | P14780 | 5/20 | 0.63 |
| ▸ | MMP8 | P22894 | 5/20 | 0.63 |
| ▸ | MMP1 | P03956 | 2/20 | 0.55 |
| ▸ | ACE | P12821 | 2/20 | 0.55 |
| ▸ | ERAP2 | Q6P179 | 2/20 | 0.54 |
| ▸ | ANPEP | P15144 | 1/20 | 0.54 |
| ▸ | ERAP1 | Q9NZ08 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6575260 | 0.89 | MMP2 (0.66) | ECE1MMP2MMP9MMP8MMP1 | |
| SCHEMBL6431194 | 0.89 | ECE1 (0.79) | ECE1MMP2MMP9MMP8MMP1 | |
| SCHEMBL8651238 | 0.85 | MMP2 (0.73) | ECE1MMP2MMP9MMP8MMP1 | |
| SCHEMBL8527781 | 0.82 | ECE1 (0.65) | ECE1 | |
| SCHEMBL8527775 | 0.82 | ECE1 (0.65) | ECE1 | |
| SCHEMBL8657319 | 0.82 | ECE1 (0.65) | ECE1 | |
| SCHEMBL6577614 | 0.81 | MMP2 (0.80) | ECE1MMP2MMP9MMP8MMP1 | |
| SCHEMBL6439250 | 0.81 | MMP2 (0.80) | ECE1MMP2MMP9MMP8MMP1 | |
| SCHEMBL7765890 | 0.81 | MMP2 (0.80) | ECE1MMP2MMP9MMP8MMP1 | |
| SCHEMBL31331902 | 0.81 | ECE1 (0.64) | ECE1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050020607-A1 | Statin-MMP inhibitor combinations | NEWTON ROGER SCHOFIELD (US) | 2005-01-27 | — | — | US | disclosed |
| US-20040176393-A1 | Statin-MMP inhibitor combinations | NEWTON ROGER SCHOFIELD (US) | 2004-09-09 | — | — | US | disclosed |
| EP-0558648-B1 | IMPROVED MATRIX METALLOPROTEASE INHIBITORS | GALARDY RICHARD E (US) | 2004-04-28 | — | — | EP | disclosed |
| EP-1366765-A1 | Use of matrix metalloproteinase inhibitors for treating neurological disorders and promoting wound healing | WARNER-LAMBERT COMPANY LLC (US) | 2003-12-03 | — | — | EP | disclosed |
| EP-1047450-B1 | ACE INHIBITOR-MMP INHIBITOR COMBINATIONS | WARNER LAMBERT CO (US) | 2002-10-02 | — | — | EP | disclosed |
| US-20020049237-A1 | Statin-MMP inhibitor combinations | NEWTON ROGER SCHOFIELD (US) | 2002-04-25 | — | — | US | disclosed |
| US-6340709-B1 | ADMINISTERING BIPHENYLSULFONAMIDE DERIVATIVE | WARNER-LAMBERT COMPANY | 2002-01-22 | — | — | US | disclosed |
| EP-1098662-A2 | COADMINISTRATION OF ACAT AND MMP INHIBITORS FOR THE TREATMENT OF ATHEROSCLEROTIC LESIONS | WARNER-LAMBERT COMPANY (US) | 2001-05-16 | — | — | EP | disclosed |
| EP-1063991-A1 | STATIN-MATRIX METALLOPROTEINASE INHIBITOR COMBINATIONS | WARNER-LAMBERT COMPANY LLC (US) | 2001-01-03 | — | — | EP | disclosed |
| EP-0663823-B1 | INHIBITION OF ANGIOGENESIS BY SYNTHETIC MATRIX METALLOPROTEASE INHIBITORS | GLYCOMED INC (US) | 2000-11-22 | — | — | EP | disclosed |
| EP-0558648-A4 | IMPROVED MATRIX METALLOPROTEASE INHIBITORS | — | 1993-11-24 | — | — | EP | disclosed |
| EP-0558635-A4 | IMPROVED MATRIX METALLOPROTEASE INHIBITORS | — | 1993-11-24 | — | — | EP | disclosed |
| EP-0558648-A1 | IMPROVED MATRIX METALLOPROTEASE INHIBITORS | GALARDY, Richard, E. (US) | 1993-09-08 | — | — | EP | disclosed |
| EP-0558635-A1 | IMPROVED MATRIX METALLOPROTEASE INHIBITORS. | GLYCOMED INC (US) | 1993-09-08 | — | — | EP | disclosed |
| US-5239078-A | Collagenase enzyme inhibitors | GLYCOMED INCORPORATED (US) | 1993-08-24 | — | — | US | disclosed |
| US-5189178-A | Preventing protein destruction | GALARDY RICHARD E (US) | 1993-02-23 | — | — | US | disclosed |
| US-5183900-A | Matrix metalloprotease inhibitors | GALARDY RICHARD E (US) | 1993-02-02 | — | — | US | disclosed |
| WO-1992009556-A1 | IMPROVED MATRIX METALLOPROTEASE INHIBITORS | GALARDY RICHARD E (US) | 1992-06-11 | — | — | WO | disclosed |
| WO-1992009563-A1 | IMPROVED MATRIX METALLOPROTEASE INHIBITORS | GLYCOMED, INC. (US) | 1992-06-11 | — | — | WO | disclosed |
| US-5114953-A | Peptides | UNIVERSITY OF FLORIDA (US) | 1992-05-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040176393-A1 | Statin-MMP inhibitor combinations | MMP9, TIMP3, MMP3 | ECE1 71/4885MMP2 19/4885MMP9 1/4885 |
| US-20050020607-A1 | Statin-MMP inhibitor combinations | MMP9, TIMP3, MMP3 | ECE1 71/4885MMP2 19/4885MMP9 1/4885 |
| US-20020049237-A1 | Statin-MMP inhibitor combinations | MMP9, TIMP3, MMP3 | ECE1 71/4885MMP2 19/4885MMP9 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.